Table 2 Baseline characteristics and clinico-pathological data of the cohort
From: Molecular profiling of BRCA1 and BRCA2 genes in Turkish patients with early-onset breast cancer
All patients (n = 67) | BRCA1-positive (n = 5) | BRCA2-positive (n = 9) | BRCA-positive (n = 14) | BRCA-negative (n = 53) | p value | |
|---|---|---|---|---|---|---|
Age at diagnosis (years)a | 40 [32;44] (39.17 ± 3.93) | 37 [32;44] (38.60 ± 4.71) | 40 [32;44] (38.0 ± 4.83) | 38.5 [32;44] (38.21 ± 4.79) | 40 [32;44] (39.43 ± 3.63) | 0.490 (BRCA-positive vs BRCA-negative) 0.689 (BRCA1-positive vs BRCA2-positive |
Patient age groups (years)b | ||||||
≤ 35 | 16 (24%) | 1 (20%) | 4 (44.5%) | 5 (%36) | 11 (%21) | 0.418 (BRCA-positive vs BRCA-negative) 0.405 (BRCA1-positive vs BRCA2-positive) |
36–40 | 22 (33%) | 2 (40%) | 1 (11%) | 3 (%21) | 19 (%36) | |
41–44 | 29 (43%) | 2 (40%) | 4 (44.5%) | 6 (%43) | 23 (%43) | |
Family history (at least one affected first, second or third degree relative with breast, ovarian, pancreatic, or prostate cancer)b | ||||||
Positive | 44 (%66) | 4 (%80) | 8 (%89) | 12 (%86) | 32 (%60) | 0.075 (BRCA-positive vs BRCA-negative) 0.648 (BRCA1-positive vs BRCA2-positive) |
Negative | 23 (%34) | 1 (%20) | 1 (%11) | 2 (%14) | 21 (%40) | |
Estrogen-receptor (ER) statusb | ||||||
Positive | 45/65 (%69) | 2/5 (%40) | 5/9 (%56) | 7/14 (%50) | 38/51 (%75) | 0.078 (BRCA-positive vs BRCA-negative) 0.576 (BRCA1-positive vs BRCA2-positive) |
Negative | 20/65 (%31) | 3/5 (%60) | 4/9 (%44) | 7/14 (%50) | 13/51 (%25) | |
Missing | 2 (%3) | – | – | – | 2 (%4) | |
Progesterone-receptor (PR) statusb | ||||||
Positive | 39/65 (%60) | 3/5 (%60) | 4/9 (%62) | 7/14 (%61) | 32/51 (%63) | 0.388 (BRCA-positive vs BRCA-negative) 0.576 (BRCA1-positive vs BRCA2-positive) |
Negative | 26/65 (%40) | 2/5 (%40) | 5/9 (%38) | 7/14 (%39) | 19/51 (%37) | |
Missing | 2 (%3) | – | – | – | 2 (%4) | |
HER2 statusb | ||||||
Positive | 22/58 (%38) | 2/4 (%50) | 5/9 (%56) | 7/13 (%54) | 15/45 (%33) | 0.179 (BRCA-positive vs BRCA-negative) 0.852 (BRCA1-positive vs BRCA2-positive) |
Negative | 36/58 (%62) | 2/4 (%50) | 4/9 (%44) | 6/13 (%46) | 30/45 (%67) | |
Missing | 9 (%13) | 1 (%20) | – | 1 (%7) | 8 (%15) | |
Triple-negative (TN)c breast cancer statusb | ||||||
Yes | 9/61 (%15) | 2/4 (%50) | 1/9 (%11) | 3/13 (%23) | 6/48 (%12.5) | 0.340 (BRCA-positive vs BRCA-negative) 0.124 (BRCA1-positive vs BRCA2-positive) |
No | 52/61 (%85) | 2/4 (%50) | 8/9 (%89) | 10/13 (%77) | 42/48 (%87.5) | |
Unknown due to lack of data | 6 (%9) | 1 (%20) | – | 1 (%7) | 5 (%10) | |